Canton Strategic Holdings, Inc. (CNTN): Nasdaq/NYSE listing notice — Hillstream BioPharma receives Nasdaq delisting notice for bid price below $1.00

Canton Strategic Holdings, Inc.

Received Nasdaq notice on Oct 27, 2022 for non-compliance with minimum bid price rule (30 consecutive days below $1.00).
Has 180 days (until Apr 25, 2023) to regain compliance by closing at $1.00+ for 10 consecutive business days.
If not compliant by Apr 25, 2023, may qualify for second 180-day period; failure leads to delisting with appeal option.
Stock continues trading under symbol HILS; company monitoring options to regain compliance.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Canton Strategic Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

October 27, 2022, Hillstream BioPharma, Inc., a Delaware corporation (the “ Company ”), received written notice (the “ Notice ”) from the Nasdaq Stock Market, LLC (“ Nasdaq ”) indicating that the bid price for the Company’s common stock (the “Common Stock”), for the last 30 consecutive business days, had closed below the minimum $1.00 per share and, as a result, the Company is not in compliance with the $1.00 minimum bid price requirement for the continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2). The Notice has no effect at this time of the Common S

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Canton Strategic Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-029848

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.